Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression

15 Feb 2024

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38364963
DOI: 10.1016/j.canlet.2024.216725

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progressionPMID 38364963Read ↗

In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasisSemantic proximity Read ↗

An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancerSemantic proximity Read ↗

CRISPR Screen Contributes to Novel Target Discovery in Prostate CancerSemantic proximity Read ↗

CRISPR/Cas9 Technology Providing a Therapeutic Landscape of Metastatic Prostate CancerSemantic proximity Read ↗

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivitiesSemantic proximity Read ↗

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expressionSemantic proximity Read ↗

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancerSemantic proximity Read ↗

Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-lossSemantic proximity Read ↗

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.Semantic proximity Read ↗

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate CancerSemantic proximity Read ↗

Cross-resistance and drug sequence in prostate cancerSemantic proximity Read ↗

A kinome-wide CRISPR screen identifies CK1α as a novel target to overcome enzalutamide resistance of prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.